Differential Ligand Binding Affinities of Human Estrogen Receptor-α Isoforms

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Lin, Amanda H Y ^a   Li, Rachel W S ^a   Ho, Eva Y W ^a   Leung, George P H ^a   Leung, Susan W S ^a   Vanhoutte, Paul M ^a   Man, Ricky Y K ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA36; ESTROGEN RECEPTOR ALPHA46; ESTROGEN RECEPTOR ALPHA66; UNCLASSIFIED DRUG; ESTRADIOL; ISOPROTEIN; LIGAND; PHYTOESTROGEN; PROTEIN BINDING;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL FREE SYSTEM; CELLULAR DISTRIBUTION; CONTROLLED STUDY; LIGAND BINDING; NUCLEOTIDE SEQUENCE; PALMITOYLATION; PROTEIN CONFORMATION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RECEPTOR BINDING; AGONISTS; ANTAGONISTS AND INHIBITORS; BINDING SITE; CELL LINE; CELL MEMBRANE; GENE EXPRESSION; GENETICS; HUMAN; LIPOYLATION; METABOLISM; PROTEIN PROCESSING;

BINDING SITES; CELL LINE; CELL MEMBRANE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; GENE EXPRESSION; HUMANS; LIGANDS; LIPOYLATION; PHYTOESTROGENS; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84876986634     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063199     Document Type: Article

References (54)

1. Ho KJ, Liao JK, (2002) Nonnuclear actions of estrogen. Arterioscler Thromb Vasc Biol 22: 1952-1961.
2. Kelly MJ, Levin ER, (2001) Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab 12: 152-156.
3. Aronica SM, Kraus WL, Katzenellenbogen BS, (1994) Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc Natl Acad Sci U S A 91: 8517-8521.
4. Szego CM, Davis JS, (1967) Adenosine 3′,5′-monophosphate in rat uterus: acute elevation by estrogen. Proc Natl Acad Sci U S A 58: 1711-1718.
5. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR, (2000) Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci U S A 97: 5930-5935.
6. Tesarik J, Mendoza C, (1995) Nongenomic effects of 17 beta-estradiol on maturing human oocytes: relationship to oocyte developmental potential. J Clin Endocrinol Metab 80: 1438-1443.
7. Losel R, Wehling M, (2003) Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol 4: 46-56.
8. Teoh H, Leung SW, Quan A, Huang M, Man GS, et al. (2000) Acetylcholine-mediated relaxation in rat thoracic aorta is enhanced following acute exposure to physiological concentrations of 17beta-estradiol. Mol Cell Biochem 207: 65-70.
9. Razandi M, Pedram A, Park ST, Levin ER, (2003) Proximal events in signaling by plasma membrane estrogen receptors. J Biol Chem 278: 2701-2712.
10. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, et al. (2000) Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87: 677-682.
11. Meyers MJ, Sun J, Carlson KE, Marriner GA, Katzenellenbogen BS, et al. (2001) Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J Med Chem 44: 4230-4251.
12. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G, et al. (2004) Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 69: 537-542.
13. Klinge CM, (2001) Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res 29: 2905-2919.
14. Pietras RJ, Szego CM, (1977) Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells. Nature 265: 69-72.
15. Pappas TC, Gametchu B, Watson CS, (1995) Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. FASEB J 9: 404-410.
16. Razandi M, Pedram A, Greene GL, Levin ER, (1999) Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol Endocrinol 13: 307-319.
17. Razandi M, Pedram A, Merchenthaler I, Greene GL, Levin ER, (2004) Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol 18: 2854-2865.
18. Flouriot G, Brand H, Denger S, Metivier R, Kos M, et al. (2000) Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. Embo Journal 19: 4688-4700.
19. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2005) Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochem Biophys Res Commun 336: 1023-1027.
20. Razandi M, Oh P, Pedram A, Schnitzer J, Levin ER, (2002) ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 16: 100-115.
21. Acconcia F, Ascenzi P, Fabozzi G, Visca P, Marino M, (2004) S-palmitoylation modulates human estrogen receptor-alpha functions. Biochem Biophys Res Commun 316: 878-883.
22. Acconcia F, Ascenzi P, Bocedi A, Spisni E, Tomasi V, et al. (2005) Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol. Mol Biol Cell 16: 231-237.
23. Billon-Gales A, Fontaine C, Filipe C, Douin-Echinard V, Fouque MJ, et al. (2009) The transactivating function 1 of estrogen receptor alpha is dispensable for the vasculoprotective actions of 17beta-estradiol. Proc Natl Acad Sci U S A 106: 2053-2058.
24. Li L, Haynes MP, Bender JR, (2003) Plasma membrane localization and function of the estrogen receptor alpha variant (ER46) in human endothelial cells. Proc Natl Acad Sci U S A 100: 4807-4812.
25. Wang Z, Zhang X, Shen P, Loggie BW, Chang Y, et al. (2006) A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. Proc Natl Acad Sci U S A 103: 9063-9068.
26. Kang L, Zhang X, Xie Y, Tu Y, Wang D, et al. (2010) Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling. Mol Endocrinol 24: 709-721.
27. Figtree GA, McDonald D, Watkins H, Channon KM, (2003) Truncated estrogen receptor alpha 46-kDa isoform in human endothelial cells: relationship to acute activation of nitric oxide synthase. Circulation 107: 120-126.
28. Lin SL, Yan LY, Liang XW, Wang ZB, Wang ZY, et al. (2009) A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells. Reprod Biol Endocrinol 7: 102.
29. Lin SL, Yan LY, Zhang XT, Yuan J, Li M, et al. (2010) ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways. PLoS One 5: e9013.
30. Kushner PJ, Hort E, Shine J, Baxter JD, Greene GL, (1990) Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol Endocrinol 4: 1465-1473.
31. Webb P, Lopez GN, Greene GL, Baxter JD, Kushner PJ, (1992) The limits of the cellular capacity to mediate an estrogen response. Mol Endocrinol 6: 157-167.
32. Katzen F, Peterson TC, Kudlicki W, (2009) Membrane protein expression: no cells required. Trends Biotechnol 27: 455-460.
33. Murdoch FE, Gorski J, (1991) The role of ligand in estrogen receptor regulation of gene expression. Mol Cell Endocrinol 78: C103-108.
34. Jiang SY, Jordan VC, (1992) Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst 84: 580-591.
35. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, et al. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138: 863-870.
36. Nath A, Atkins WM, Sligar SG, (2007) Applications of phospholipid bilayer nanodiscs in the study of membranes and membrane proteins. Biochemistry 46: 2059-2069.
37. Katzen F, Fletcher JE, Yang JP, Kang D, Peterson TC, et al. (2008) Insertion of membrane proteins into discoidal membranes using a cell-free protein expression approach. J Proteome Res 7: 3535-3542.
38. Stricker R, Eberhart R, Chevailler MC, Quinn FA, Bischof P, (2006) Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer. Clin Chem Lab Med 44: 883-887.
39. Salomonsson M, Carlsson B, Haggblad J, (1994) Equilibrium hormone binding to human estrogen receptors in highly diluted cell extracts is non-cooperative and has a Kd of approximately 10 pM. J Steroid Biochem Mol Biol 50: 313-318.
40. Levin ER, (2009) Plasma membrane estrogen receptors. Trends in Endocrinology and Metabolism 20: 477-482.
41. Keung W, Vanhoutte PM, Man RY, (2005) Nongenomic responses to 17beta-estradiol in male rat mesenteric arteries abolish intrinsic gender differences in vascular responses. Br J Pharmacol 146: 1148-1155.
42. Lin AH, Leung GP, Leung SW, Vanhoutte PM, Man RY, (2011) Genistein enhances relaxation of the spontaneously hypertensive rat aorta by transactivation of epidermal growth factor receptor following binding to membrane estrogen receptors-alpha and activation of a G protein-coupled, endothelial nitric oxide synthase-dependent pathway. Pharmacol Res 63: 181-189.
43. Wakeling AE, Dukes M, Bowler J, (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867-3873.
44. Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, et al. (2002) Antagonists selective for estrogen receptor alpha. Endocrinology 143: 941-947.
45. Compton DR, Sheng S, Carlson KE, Rebacz NA, Lee IY, et al. (2004) Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity. J Med Chem 47: 5872-5893.
46. Stauffer SR, Coletta CJ, Tedesco R, Nishiguchi G, Carlson K, et al. (2000) Pyrazole ligands: structure-affinity/activity relationships and estrogen receptor-alpha-selective agonists. J Med Chem 43: 4934-4947.
47. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, et al. (2006) Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2: 207-212.
48. Morello KC, Wurz GT, DeGregorio MW, (2002) SERMs: current status and future trends. Crit Rev Oncol Hematol 43: 63-76.
49. Vera R, Galisteo M, Villar IC, Sanchez M, Zarzuelo A, et al. (2005) Soy isoflavones improve endothelial function in spontaneously hypertensive rats in an estrogen-independent manner: role of nitric-oxide synthase, superoxide, and cyclooxygenase metabolites. J Pharmacol Exp Ther 314: 1300-1309.
50. Xu YC, Yeung DK, Man RY, Leung SW, (2006) Kaempferol enhances endothelium-independent and dependent relaxation in the porcine coronary artery. Mol Cell Biochem 287: 61-67.
51. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, et al. (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325: 756-762.
52. Wells JW (1992) Analysis and interpretation of binding at equilibrium. In: Hulme EC, editor. Receptor-ligand interactions: a practical approach. Oxford-UK: IRL Press. 289-397.
53. Hulme EC, Birdsall NJM (1992) Strategy and tactics in receptor-binding studies. In: Hulme EC, editor. Receptor-ligand interactions: a practical approach. Oxford-UK: IRL Press. 63-176.
54. Schults JR, Ruppel PI, Johnson MA (1988) Biopharmaceutical Statistics for Drug Development. In: Peace KE, editor. Biopharmaceutical statistics for drug development. New York: M. Dekker. 21-82.